Journal of lower genital tract disease · 2026
Upadacitinib for the Treatment of Recalcitrant Vulvar Lichen Sclerosus.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kenyon Courtney M, Rhoads Jamie W, Cocks Margaret M
Аннотация
OBJECTIVES: Incompletely treated vulvar lichen sclerosus can lead to major complications and reduced quality of life. Limited treatment options beyond super-potent topical steroids are available for these recalcitrant cases.
METHODS: In this descriptive, retrospective case series, 3 female patients ages 36-63 presenting with recalcitrant, biopsy-proven vulvar lichen sclerosus were treated with oral upadacitinib at a dosage of 15 mg daily and monitored at 1-2 month intervals.
RESULTS: All 3 patients experienced clinical improvement in signs of lichen sclerosus and a decrease in symptom severity with minimal side effects.
CONCLUSIONS: Upadacitinib may be an effective treatment option for recalcitrant vulvar LS. More robust studies are needed to fully evaluate the efficacy and limitations of JAK inhibitors in treating lichen sclerosus.
METHODS: In this descriptive, retrospective case series, 3 female patients ages 36-63 presenting with recalcitrant, biopsy-proven vulvar lichen sclerosus were treated with oral upadacitinib at a dosage of 15 mg daily and monitored at 1-2 month intervals.
RESULTS: All 3 patients experienced clinical improvement in signs of lichen sclerosus and a decrease in symptom severity with minimal side effects.
CONCLUSIONS: Upadacitinib may be an effective treatment option for recalcitrant vulvar LS. More robust studies are needed to fully evaluate the efficacy and limitations of JAK inhibitors in treating lichen sclerosus.